PMcardio vs EchoNext
AI Verdict
Choose PMcardio if…
Choose PMcardio if you need a versatile, real-time AI-powered ECG interpretation tool for rapid assessment of over 50 cardiac conditions, including acute events like STEMI and OMI, in various clinical settings. Its mobile app deployment and freemium model make it accessible for individual clinicians and emergency medical services seeking immediate, expert-level ECG analysis and treatment recommendations.
View PMcardio →Choose EchoNext if…
Choose EchoNext if your primary goal is to screen for hidden structural heart disease, such as heart failure, valve disease, and pulmonary hypertension, using standard ECGs. This FDA-cleared tool is ideal for broad access across major hospitals to community practices, aiming to detect underlying conditions that might otherwise be missed through traditional ECG interpretation, potentially leading to earlier intervention.
View EchoNext →When choosing between PMcardio and EchoNext, physicians should consider their primary diagnostic focus and workflow. PMcardio is a CE-certified AI platform designed for rapid, comprehensive interpretation of standard ECGs, identifying over 50 cardiac conditions including STEMI/OMI, arrhythmias, and reduced LVEF. Its strength lies in providing instant, expert-level interpretations at the point of care, making it suitable for a broad range of healthcare professionals in settings like emergency medicine, internal medicine, and cardiology for immediate diagnostic support. The freemium model also allows for initial exploration before committing to a paid plan.
EchoNext, an FDA-cleared AI tool, specializes in analyzing standard ECGs to detect hidden structural heart disease, such as heart failure, valve disease, and pulmonary hypertension. Its key practical difference is this specific focus on structural abnormalities that might otherwise be missed on a routine ECG, offering a valuable screening tool for conditions that often require further investigation. Physicians in family medicine, hospital medicine, or internal medicine who are looking to proactively identify patients at risk for these underlying structural issues might find EchoNext particularly beneficial, especially when integrated into existing clinical decision support platforms like OpenEvidence. The pricing model for EchoNext is subscription-based, starting at $600/month, reflecting its specialized diagnostic capability.
Ultimately, the choice depends on the physician’s immediate needs. If the goal is rapid, broad-spectrum ECG interpretation for acute and common cardiac conditions with a flexible pricing structure, PMcardio is a strong contender. If the priority is to screen for subtle signs of hidden structural heart disease using standard ECGs, particularly in a primary care or general hospital setting, EchoNext offers a specialized and FDA-cleared solution.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | PMcardio | EchoNext |
|---|---|---|
| Pricing | Freemium | Starts at $600/month |
| Deployment | Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Pending AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
PMcardioPMcardio offers deployment as a mobile app (iOS and Android) and a web platform, allowing for flexible access. It also provides a free plan with 5 ECG analyses per month, making it accessible for individual clinicians to try. EchoNext is available through the OpenEvidence platform, and while designed for broad access, its direct user experience and ease of individual adoption are less clear from the provided information.
Clinical Value
PMcardioPMcardio is CE-certified and clinically validated in over 25 studies, detecting more than 50 cardiac conditions, including STEMI/OMI, reduced LVEF, and various arrhythmias. It has demonstrated superior accuracy in detecting acute OMI compared to STEMI criteria and has shown to reduce false STEMI alarms. EchoNext is FDA-cleared for detecting hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, and has shown high accuracy in validation studies, outperforming cardiologists in some instances. However, PMcardio's broader range of detectable conditions and extensive validation in over 25 studies suggest a wider clinical utility at present.
Pricing & Value
PMcardioPMcardio offers a freemium model with 5 free ECG analyses per month, making it highly accessible for individual users to evaluate its value before committing to a paid plan. EchoNext starts at $600/month with tiered pricing and an implementation fee, which may be a significant barrier for smaller practices or individual clinicians. PMcardio's transparent freemium model provides a clear advantage in terms of initial value and accessibility.
Enterprise Readiness
PMcardioPMcardio explicitly highlights its enterprise-ready deployment, with integrations for EHR/CVIS and EMS systems, and the ability to scale across campuses and care settings. It also emphasizes a unified platform for various cardiac care pathways and comprehensive security and compliance. EchoNext is available through the OpenEvidence platform and targets broad access from major hospitals to community practices, but its specific enterprise integration capabilities are less detailed than PMcardio's.
Innovation
PMcardioPMcardio features 'Queen of Hearts' for STEMI and OMI detection, 'LVsense' for reduced LVEF detection, and 'ECGxplain' for visual AI explainability with heatmaps, showcasing advanced AI capabilities and transparency. It has also received FDA Breakthrough Device Designation for its STEMI AI ECG Model. EchoNext is innovative as the world's first FDA-cleared AI tool for detecting hidden structural heart disease from ECGs. However, PMcardio's suite of specialized AI features and its focus on explainability give it an edge in innovation.
Support & Docs
PMcardioPMcardio provides a Help Center with user-friendly tutorials and manuals, FAQs, and detailed regulatory and security documentation. This suggests a comprehensive approach to user support and information. While EchoNext is available through OpenEvidence, specific details about its dedicated support and documentation resources are not readily available in the provided information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | PMcardio | EchoNext |
|---|---|---|
| Name | PMcardio | EchoNext |
| Company | Powerful Medical | Pathway Labs |
| Tagline | AI that reads ECGs in seconds | How's your heart? |
| Key Features (ECG Analysis) | Instant AI-powered ECG interpretations, Detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders), Queen of Heartsu2122 - STEMI and OMI Detection, LVsenseu2122 - Reduced LVEF Detection, ECGxplainu2122 - Visual AI Explainability with heatmaps, Core AI - Detects 36 core diagnoses, Automatic analysis of heart rate, axis, P wave, PR, QRS, and QT/QTc intervals, Culprit Artery AI confidence scores with 3D heart visualization | AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs |
| CE Certification | CE-certified | Not specified |
Videos
Demos, reviews, and walkthroughs featuring PMcardio and EchoNext.